A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- John Sweetenham, MD
The Cleveland Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Jewish General Hospital - Sir Mortimer B. Davis
Montreal, Quebec, Canada
- Providence Saint-Joseph Medical Center
Burbank, California, United States
- New York Medical College
Valhalla, New York, United States
- the Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio, United States
- Scott and White Memorial Hospital
Temple, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2008
- Primary completion
- 30 Jun 2011
- Completion
- 30 Sept 2011
- Last update posted
- 13 Jul 2011
- Registered enrollment
- 25
- Registry id
- NCT00768339
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.